GHK-Cu: Copper Tripeptide with the Broadest Human Evidence on This Desk

The short version

GHK-Cu is a copper tripeptide — the three-amino-acid sequence Gly-His-Lys chelated to a copper(II) ion. It is not a novel synthetic compound but a molecule found naturally in human plasma; plasma GHK concentrations decline from approximately 200 ng/mL at age 20 to approximately 80 ng/mL by age 60 ^[21].

In contrast to the other compounds on this desk, GHK-Cu has a substantial topical human evidence record. Controlled studies document increased collagen production in treated subjects, improvements in skin laxity and wrinkle depth, and statistically significant hair-count increases in men with androgenetic alopecia compared with placebo ^[20][21]. It is a legal cosmetic ingredient (Copper Tripeptide-1) in the US, EU, and UK for topical use.

The important caveats: most of the broader anti-aging and gene-expression claims rest on cell and rodent studies, many originating from a single investigator group. The key delivery challenge — GHK's poor skin permeability (clogP -2.24) — has been a limiting factor in translating laboratory concentrations to topical efficacy ^[18]. Injectable or systemic use is unapproved and has no validated human pharmacokinetic basis. This page summarizes the published evidence; it does not recommend use and lists no doses.

What it is

GHK-Cu is the Glycyl-L-Histidyl-L-Lysine copper(II) complex: a linear tripeptide (Gly-His-Lys) chelated 1:1 to a Cu(II) ion through the histidine imidazole nitrogen, the glycine alpha-amino nitrogen, and the deprotonated glycine-histidine amide nitrogen, leaving the lysine side chain available for additional interactions. Molecular formula: C14H23CuN6O4+. Synonyms include Copper Tripeptide-1 (cosmetic INCI name), Prezatide copper, and Tripeptide-1 (copper).

The GHK sequence occurs endogenously in the alpha-2(I) chain of type I collagen and in SPARC/osteonectin. It is a copper-chelating peptide, distinct from a copper salt — the chelation structure is mechanistically essential: the free GHK tripeptide without copper does not reproduce key effects such as matrix metalloproteinase-2 stimulation documented with the copper-bound form. Topical GHK-Cu is an approved cosmetic ingredient; injectable or oral use is unapproved and research-only.

How it works

GHK-Cu operates as both a copper chaperone and a pleiotropic signaling molecule in the picomolar-to-nanomolar concentration range ^[21]. Its documented mechanisms include:

• Matrix synthesis stimulation: In dermal fibroblasts, it stimulates synthesis of collagen, elastin, glycosaminoglycans (including dermatan sulfate and chondroitin sulfate), and the proteoglycan decorin ^[21].
• MMP rebalancing: It modulates matrix metalloproteinase activity against TIMP inhibitors, supporting tissue remodeling rather than degradation.
• Gene expression: A Connectivity Map analysis reported GHK altering expression of approximately 31.2% of human genes at a 50%-or-greater change threshold — 59% upregulated (wound-repair, DNA-repair, antioxidant, and ubiquitin-proteasome pathways) and 41% downregulated (NF-kB-driven inflammation) ^[19]. The widely cited figure of "~4,000 genes" is an extrapolation; the ≥50% threshold analysis in the published paper covers approximately 2,100 genes.
• Copper-enabled enzymatic activity: The bound Cu(II) enables lysyl oxidase-mediated collagen and elastin cross-linking and provides superoxide-dismutase-like antioxidant activity; if the complex is disrupted (e.g., by strong reducing agents), free copper may become pro-oxidant.
• Topical delivery challenge: GHK has a clogP of -2.24, indicating poor stratum-corneum permeability. A human skin penetration study found a permeability coefficient of 2.43 × 10⁻⁴ cm/h and a dermal copper depot of 97 μg/cm² retained after 48 hours ^[22]. Enhancement strategies include palmitoylation (raising clogP to 1.14) and microneedle pretreatment ^[18].

What the research shows

Topical anti-wrinkle and collagen review (human clinical trials, 2025) ^[18]: GHK-Cu treatment increased procollagen synthesis in 70% of subjects versus 50% for vitamin C and 40% for retinoic acid in reviewed controlled studies. Evaluated palmitoylation and microneedle strategies for delivery enhancement.

Gene-expression analysis (human, 2018) ^[19]: Connectivity Map analysis showed GHK altering expression of approximately 31.2% of human genes at a ≥50% change threshold, with upregulation concentrated in wound-repair, DNA-repair, antioxidant, and ubiquitin-proteasome gene sets, and suppression of NF-kB-driven inflammatory gene sets.

Hair-growth RCT in androgenetic alopecia (human, n=45 men, 2016) ^[20]: A 6-month trial of a 5-aminolevulinic acid and glycyl-histidyl-lysine complex (ALAVAX) increased hair count by 52.6 (100 mg/mL) and 71.5 (50 mg/mL) versus 9.6 for placebo (p < 0.05). No adverse events in any group. This is the strongest controlled human efficacy signal for a GHK-containing topical.

Canonical skin-regeneration review (human, 2015) ^[21]: Documented plasma GHK decline from approximately 200 ng/mL at age 20 to 80 ng/mL by age 60. Collagen increased in 70% of topically treated women versus 50% for vitamin C and 40% for retinoic acid. Placebo-controlled improvements in skin laxity, clarity, fine lines, wrinkle depth, and density.

Human skin penetration study (ex vivo, 2011) ^[22]: Copper permeability coefficient 2.43 ± 0.51 × 10⁻⁴ cm/h through dermatomed skin; 136.2 ± 17.5 μg/cm² permeated over 48 hours; 97 ± 6.6 μg/cm² retained as a dermal depot. Establishes the pharmacokinetic basis for topical formulation strategy.

Reported effects, cautions, and safety

Community-reported effects (anecdotal, not clinical evidence)

The most commonly reported experience with topical GHK-Cu products is firmer, more elastic-feeling skin — users describe a gradual increase in skin tautness and what they characterize as a 'bouncy' texture after several weeks of consistent twice-daily use. Softer fine lines and shallower wrinkles are also frequently reported, typically emerging cumulatively over 6–12 weeks. Many users note improved hydration and a plumper appearance within the first week or two, often before more structural changes are apparent. Less common but periodically reported: a more even skin tone and faded marks, and — for those applying to the scalp — reduced hair shedding and denser-looking hair over 3–6 months. Adverse reports center on skin irritation (redness, itching, stinging, or dryness), particularly with high concentrations or on sensitive skin; occasional breakouts described as a purging phase; and a small minority reporting temporary worsening of pigmentation. All are anecdotal reports, not controlled measurements.

Safety cautions (citation-grounded)

• Injectable and systemic use is unapproved and unstudied in humans: All human evidence is topical. Injecting GHK-Cu has no validated pharmacokinetic basis in humans; the free peptide is broken down quickly in plasma in rodent studies. This route is unapproved and experimental.
• Copper accumulation risk with prolonged systemic use: Repeated systemic copper input could theoretically disturb copper-zinc balance, a concern in conditions such as Wilson's disease. No human copper-toxicity cases are attributed to GHK-Cu in the literature; this is a theoretical caution for non-topical use.
• Pigmentation changes: Copper supports tyrosinase-driven melanin production. People with melasma or stubborn dark spots may experience variable responses.
• Skin irritation on sensitive skin or at high concentration: Well-documented in community reports; patch-testing is standard advice ^[18].
• Formulation compatibility: Vitamin C (ascorbic acid) at low pH and AHA/BHA exfoliating acids can disrupt the copper-peptide complex or stack irritation. The copper complex is most stable at mildly acidic-to-neutral pH ^[18].
• Copper coordination is required: The plain GHK tripeptide without the Cu(II) ion does not reproduce key documented bioactivities; product integrity and pH stability matter for efficacy.
• Human evidence is limited in scale and largely topical: Broader anti-aging and gene-expression claims rest substantially on cell and rodent models, with a large share originating from a single investigator group. Controlled human studies are small (n typically 13–71) ^[18][21].

Where it fits in this research desk

GHK-Cu is the compound on this desk with the broadest direct human evidence — though that evidence is concentrated in small topical dermatology and hair-loss trials, not in large clinical programs. Its standing as a legal cosmetic ingredient gives it a regulatory clarity the other compounds on this desk lack. Its story illustrates a different kind of evidence problem: not absence of human data, but data confined to one route and tissue type, with a wide gap between what cell and rodent studies suggest is possible and what controlled human trials have confirmed.

For a direct comparison of evidence maturity across all five compounds, see the comparison page.